BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  ASGCT: Rocket Ready to Launch, Mustang Bio’s Successful Trial and Voyager’s Early Data

  The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.

  May 20, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Bio NC

  Inceptor Bio Snags $37M for Three-Pronged Immuno-Oncology Platforms

  Fueled by $37 million in Series A financing, N.C.-based Inceptor Bio is advancing three, next-generation approaches to immuno-oncology, including a CAR-T program that is expected to be in the clinic next year.

  May 20, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Clinical Catch-Up: Amgen, AstraZeneca, Avillion Attack Asthma

  Closing out the month of May, plenty of companies presented or announced clinical trial updates and news. Here’s a look.

  May 20, 2022

   · 

  10 min read

   · 

  Mark Terry
• 

  Drug Development

  ASLAN, Kymera Target Atopic Dermatitis at Dermatology Meeting

  Anyone who has dealt with inflammatory skin conditions is familiar with what seems like a near-constant itch. That could become a thing of the past if ASLAN Pharma has something to say about it.

  May 20, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Celebrities are Bringing Awareness to Breast Cancer

  Celebrities’ struggles with breast cancer are bringing new awareness to the importance of screening - particularly because new therapies like Radius Health’s elacestrant are on the horizon.

  May 20, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Researchers Develop CRISPR Mechanism to Edit Multiple DNA Sites at Once

  Rice University researchers used the foundation of CRISPR/Cas9 technology and developed “drive-and-process” arrays, or DAP for short.

  May 20, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Drug Development

  Following Patient Death, FDA Puts Foghorn Study on Partial Hold

  The hold follows a serious adverse event in which a study participant died after developing possible differentiation syndrome.

  May 20, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano, M.S.
• 

  Drug Development

  Athersys Shares Pummeled as Ischemic Stroke Study Misses Endpoint

  A study conducted by Athersys’ partner Healios on a potential treatment for ischemic stroke failed to meet the primary endpoint as its stock dropped 43%.

  May 20, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  BridgeBio Continues Comeback with Positive Epidermolysis Bullosa Data

  BridgeBio Pharma and its affiliate Phoenix Tissue Repair announced positive data from their Phase II clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

  May 20, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Rack Up Another Win for Dupixent, This One as First Treatment for EoE

  The approval marks the first for EoE, a chronic, progressive type 2 inflammatory disease that damages the eosinophilic esophagitis and prevents it from working properly.

  May 20, 2022

   · 

  3 min read

   · 

  Alex Keown